Investing
2 Biotech Lead 'Best Ideas List For 2012' (VPHM, MNTA)
Published:
Last Updated:
2012 is already seeing a wave of biotech mergers and many are expecting more mergers and more positive developments in the emerging-pharma sector. We have featured many top analyst favorite picks and highest upside candidates in biotech for 2012, but Zacks Investment Research has two of its “12 Stocks for 2012” listed in the emerging-pharma sector. Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) and Viropharma Inc. (NASDAQ: VPHM) were on this list, making biotech literally one-sixth of the best ideas for the year.
Momenta specializes in the characterization and process engineering of complex molecules and it is called “up and coming with strong profitability, a clearly inexpensive stock price relative to its industry, increasing sales and income, and analyst stock upgrades.” FULL NOTE ON MOMENTA
Viropharma is into therapeutic products that address serious diseases. Zacks noted that it is expecting better sales that boosted its stock. It also noted analyst upgrades and said, “Profitability and margins remain strong and the annual sales should make profits higher as well.” FULL NOTE ON VIROPHARMA
Read Also: Top Analyst Biotech Stocks For 2012
As far as how this compares, see below:
JON C. OGG
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.